Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mologen AG

www.mologen.com

Latest From Mologen AG

InDex's Lead TLR9 Agonist Shows Promise In Ulcerative Colitis

A Toll-like receptor-9 agonist under development by Sweden’s InDex Pharmaceuticals showed encouraging clinical responses in top-line results in patients with active ulcerative colitis not responding to other agents. Its novel mechanism of action and relatively benign side effect profile makes it a prime candidate to combine with biologic agents.

 

Gastrointestinal Clinical Trials

Mologen To Pursue Combinations Only After Lefitolimod’s Solo IMPALA Failure

Mologen’s CEO tells Scrip the German biotech will only pursue combination studies in future after its lead candidate lefitolimod failed as a monotherapy in a pivotal trial treating metastatic colorectal cancer patients.

Clinical Trials Commercial

Key Catalyst In August For Mologen As IMPALA Phase III Colorectal Cancer Reports

Mologen CEO says next month’s pivotal trial topline readout on its lead asset lefitolimod will be important for the German-based immunotherapy pioneer of DNA-based TLR9 agonists.

Clinical Trials Companies

Appointments: Senior Hires At IGM, Cell Medica, Mologen, Navitor, Tenaya, Oncobiologics, Provention Bio And Centrexion

New CEOs have been appointed at Cell Medica, Mologen, Navitor Pharmaceuticals, Tenaya Therapeutics and Oncobiologics, while a new CMO has been recruited to IGM Biosciences, a vice president of clinical development at Provention Bio and a CFO at Centrexion Therapeutics.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Mologen Holding AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Mologen AG
  • Senior Management
  • Ignacio Faus, PhD, CEO
    Walter Miller, CFO
    Matthias Baumann, MD, CMO
  • Contact Info
  • Mologen AG
    Phone: (49) 30 84 1788 0
    Fabeckstr. 30
    Berlin, 14195
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register